Oncology-Global Evidence and Value Development, Medical Affairs , Sanofi, Cambridge, MA , USA.
Leuk Lymphoma. 2014 Mar;55(3):595-600. doi: 10.3109/10428194.2013.813500. Epub 2013 Jul 29.
Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) are three classic BCR ABL fusion gene-negative chronic myeloproliferative neoplasms (MPNs). Though rare, it is important to understand the burden of illness of these disorders for public health planning, healthcare insurers and pharmaceutical manufacturers. Therefore, we have described the incidence of MF and prevalence of MF, ET and PV in the United States between 2008 and 2010 based on data from two large health plans. The incidence of primary MF was about 1 per 100 000 per year and did not vary over the study years. The prevalence of PV (44-57 per 100 000) and ET (38-57 per 100 000) was much higher than that of MF (4-6 per 100 000) or subgroups containing MF (post-PV MF = 0.3-0.7 per 100 000; post-ET MF = 0.5-1.1 per 100 000). Additional research using other national databases and/or study designs is needed to substantiate these findings.
骨髓纤维化（MF）、真性红细胞增多症（PV）和特发性血小板增多症（ET）是三种经典的 BCR ABL 融合基因阴性慢性骨髓增生性肿瘤（MPN）。尽管罕见，但了解这些疾病的疾病负担对于公共卫生规划、医疗保健保险公司和制药制造商来说非常重要。因此，我们根据两个大型健康计划的数据，描述了 2008 年至 2010 年美国 MF、MF、ET 和 PV 的发病率和患病率。原发性 MF 的发病率约为每年每 10 万人 1 例，且在研究期间没有变化。PV（44-57/10 万人）和 ET（38-57/10 万人）的患病率明显高于 MF（4-6/10 万人）或包含 MF 的亚组（PV 后 MF=0.3-0.7/10 万人；ET 后 MF=0.5-1.1/10 万人）。需要使用其他国家数据库和/或研究设计进行更多研究，以证实这些发现。
